| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Total revenue | 5,486 | 1,901 | -7,162* | 12,500 |
| Cost of sales | 280 | 1,076 | 105* | - |
| Selling, general and administrative | 39,378 | 44,960 | 30,864* | 27,596 |
| Research and development | 0 | 0 | -608* | 3,791 |
| Total operating expenses | 39,658 | 46,036 | 30,360* | 31,387 |
| Loss from operations | -34,172 | -44,135 | -37,522* | -18,887 |
| Other (expense) income | -13 | 3 | -520* | -14 |
| Interest income | 2,270 | 2,644 | 3,086* | 2,201 |
| Total other income, net | 2,257 | 2,647 | 2,565* | 2,187 |
| Net loss before income taxes | -31,915 | - | -34,957* | -16,700 |
| Income tax expense | 3 | - | -248* | 0 |
| Net loss | -31,918 | -41,488 | -34,709* | -16,700 |
| Unrealized gain on marketable securities | -179 | -692 | -110* | 189 |
| Comprehensive loss | -32,097 | -42,180 | -34,819 | -16,511 |
| Basic EPS | -1.02 | -1.32 | -1.168 | -0.59 |
| Diluted EPS | -1.02 | -1.32 | -1.168 | -0.59 |
| Basic Average Shares | 31,374,311 | 31,352,702 | 29,819,902 | 28,540,519 |
| Diluted Average Shares | 31,374,311 | 31,352,702 | 29,819,902 | 28,540,519 |
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)